Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
AbstractIdiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis is complex and encompasses multiple molecular pathways. The first-generation antifibrotics pirfenidone and nintedanib, approved more than 10 years ago, have been shown to reduce the rate of progression, increase the length of life for patients with IPF, and work for other fibrotic lung diseases. In the last two decades, most clinical trials on IPF have failed to meet the primary endpoint and an urgent unmet need remains to identify age nts or treatment strategies that can stop disease progression. The pharmacotherapeutic la...
Source: Drugs - October 26, 2023 Category: Drugs & Pharmacology Source Type: research
Zuranolone: First Approval
This article summarizes the milestones in the development of zuranolone leading to this first approval. (Source: Drugs)
Source: Drugs - October 26, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Rozanolixizumab: First Approval
(Source: Drugs)
Source: Drugs - October 20, 2023 Category: Drugs & Pharmacology Source Type: research
Pozelimab: First Approval
AbstractPozelimab (pozelimab-bbfg; VEOPOZ ™) is a fully human immunoglobulin (Ig) G4P (i.e. IgG4 with a proline substitution to promote stabilization of the disulfide bonds between the two heavy chains) monoclonal antibody developed by Regeneron Pharmaceuticals Inc., to block the activity of complement factor 5 (C5) and prevent diseases mediated by the complement pathway. In August 2023, pozelimab received its first approval for the treatment of adults, and paediatric patients aged ≥ 1 year with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease, in the USA. It is the first US FDA-approved...
Source: Drugs - October 19, 2023 Category: Drugs & Pharmacology Source Type: research
Tafolecimab: First Approval
This article summarizes the milestones in the development of tafolecimab leading to this first approval for the treatment of adults with primary hyperlipidemia and mixed dyslipidemia. (Source: Drugs)
Source: Drugs - October 17, 2023 Category: Drugs & Pharmacology Source Type: research
Lotilaner Ophthalmic Solution 0.25%: First Approval
This article summarizes the milestones in the development of lotilaner ophthalmic solution 0.25% leading to this first approval for the treatment ofDemodex blepharitis in the USA. (Source: Drugs)
Source: Drugs - October 16, 2023 Category: Drugs & Pharmacology Source Type: research
Current Medical Therapy for Adenomyosis: From Bench to Bedside
AbstractAdenomyosis, characterized by the growth of endometrial tissue within the uterine wall, poses significant challenges in treatment. The literature primarily focuses on managing abnormal uterine bleeding (AUB) and dysmenorrhea, the main symptoms of adenomyosis. Nonsteroidal anti-inflammatory drugs (NSAIDs) and tranexamic acid provide limited support for mild symptoms or symptom re-exacerbation during hormone therapy. The levonorgestrel-releasing intrauterine system (LNG-IUS) is commonly employed in adenomyosis management, showing promise in symptom improvement and reducing uterine size, despite the lack of standardiz...
Source: Drugs - October 14, 2023 Category: Drugs & Pharmacology Source Type: research
The Place of Cannabinoids in the Treatment of Gynecological Pain
AbstractCannabis sativa (L), a plant with an extensive history of medicinal usage across numerous cultures, has received increased attention over recent years for its therapeutic potential for gynecological disorders such as endometriosis, chronic pelvic pain, and primary dysmenorrhea, due at least in part to shortcomings with current management options. Despite this growing interest, cannabis inhabits an unusual position in the modern medical pharmacopoeia, being a legal medicine, legal recreational drug, and an illicit drug, depending on jurisdiction. To date, the majority of studies investigating cannabis use have found...
Source: Drugs - October 13, 2023 Category: Drugs & Pharmacology Source Type: research
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
AbstractHyperuricemia with consequent monosodium urate crystal deposition leads to gout, characterized by painful, incapacitating inflammatory arthritis flares that are also associated with increased cardiovascular event and related mortality risk. This narrative review focuses on emerging pharmacologic urate-lowering treatment (ULT) and management strategies in gout. Undertreated, gout can progress to palpable tophi and joint damage. In oral ULT clinical trials, target serum urate of< 6.0 mg/dL can be achieved in ~ 80 –90% of subjects, with flare burden reduction by 1–2 years. However, real-world ULT results are fa...
Source: Drugs - October 11, 2023 Category: Drugs & Pharmacology Source Type: research
